Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients

[Display omitted] Evaluation of biologic therapy response is vital to monitor its effectiveness. Authors have proposed various response criteria including good responder, super-responder, non-responder, and clinical remission. To ascertain the prevalence of response and clinical remission after long...

Full description

Saved in:
Bibliographic Details
Published in:Archivos de bronconeumología (English ed.) 2024-01, Vol.60 (1), p.23-32
Main Authors: Valverde-Monge, Marcela, Sánchez-Carrasco, Patricia, Betancor, Diana, Barroso, Blanca, Rodrigo-Muñoz, José Manuel, Mahillo-Fernández, Ignacio, Arismendi, Ebymar, Bobolea, Irina, Cárdaba, Blanca, Cruz, María Jesús, Del Pozo, Victoria, Domínguez-Ortega, Javier, González-Barcala, Francisco Javier, Olaguibel, José María, Luna-Porta, Juan Alberto, Martínez-Rivera, Carlos, Mullol, Joaquim, Muñoz, Xavier, Peleteiro-Pedraza, Lorena, Picado Valles, Cesar, Plaza, Vicente, Quirce, Santiago, Rial, Manuel Jorge, Soto-Retes, Lorena, Valero, Antonio, Sastre, Joaquín
Format: Article
Language:English
Subjects:
Anti-Asthmatic Agents
Asthma - drug therapy
Biologic treatment
Biological Products - therapeutic use
Clinical remission
Humans
Immunosuppressive Agents - therapeutic use
Non-responders
Omalizumab - therapeutic use
Predictors
Responders
Severe asthma
Severe uncontrolled asthma
Super-responders
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Evaluation of biologic therapy response is vital to monitor its effectiveness. Authors have proposed various response criteria including good responder, super-responder, non-responder, and clinical remission. To ascertain the prevalence of response and clinical remission after long-term treatment (>6 months) of anti-IgE and anti-IL-5/IL-5Rα biologics, compare these results with existing criteria, and identify predictors for non-responders and clinical remission. A multicenter, real-life study involving severe asthma patients in Spain. Various outcomes were assessed to gauge response and clinical remission against established criteria. The study included 429 patients, 209 (48.7%) omalizumab, 112 (26.1%) mepolizumab, 19 (4.4%) reslizumab and 89 (20.7%) benralizumab, with a mean treatment duration of 55.3±38.8 months. In the final year of treatment, 218 (50.8%) were super-responders, 173 (40.3%) responders, 38 (8.9%) non-responders, and clinical remission in 116 (27%), without differences among biologics. The short-term non-responders (
ISSN:0300-2896
1579-2129
DOI:10.1016/j.arbres.2023.11.011